ALLY BRIDGE GROUP NY LLC
Q4 2022 Form 13-F
NEW YORK, NEW YORK
CIK 0001822947
· CRD 291072
· SEC-registered investment adviser
$102.8M Reported Value Total
ALLY BRIDGE GROUP (NY) LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $360,023,492, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $340.7M gross asset value
Hedge Fund: $340.7M
Source: Form ADV filed 2026-03-31
Reported value
$102.8M
Quarter over quarter
-8.2%
Holdings
30
Top-10 concentration
59.6%
Filing Structure
Reports holdings for
- Yu Fan · File #028-20833 · Q1 2024 – Q1 2026 · declared by one filing
- Fan Yu (not a 13F filer in our records) · Q4 2020 – Q4 2020 · declared by one filing
Key People
Form ADV owners & control persons
Fan Yu
SHAREHOLDER AND DIRECTOR
Slanix Paul T Alex
PRESIDENT & PORTFOLIO MANAGER
Michael Novick Bendetson
COO, HEAD OF LEGAL & CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2022 13F record
Q4 2022 13F filing summary
| Period of report | December 31, 2022 |
|---|---|
| Filed | February 14, 2023 |
| Form | 13F-HR |
| Reported value | $102.8M |
| Positions | 30 |
| Change in reported value | -32.1% |
| New positions | 6 |
| Exited positions | 15 |
| Position turnover | 46.7% |
| Top-10 concentration | 59.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
23 | $113.1M |
|
Q1 2026 13F
Filed May 18, 2026
|
21 | $123.8M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
13 | $96.0M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
18 | $164.2M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
24 | $120.2M |
|
Q1 2025 13F
Filed May 15, 2025
|
28 | $110.9M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
30 | $116.6M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
29 | $186.8M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
25 | $167.9M |
|
Q1 2024 13F
Filed May 15, 2024
|
22 | $179.9M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
22 | $167.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
19 | $85.2M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
17 | $82.6M |
|
Q1 2023 13F
Filed May 15, 2023
|
18 | $76.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
30 | $102.8M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
39 | $151.5M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
22 | $109.7M |
|
Q1 2022 13F
Filed May 16, 2022
|
21 | $134.9M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
30 | $286.1M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
29 | $340.1M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RARE ULTRAGENYX PHARMACEUTICAL IN | $8.6M | 8.35% |
| 2 | WHWK AADI BIOSCIENCE INC | $8.1M | 7.9% |
| 3 | ACAD ACADIA PHARMACEUTICALS INC | $7.6M | 7.35% |
| 4 | MRSN MERSANA THERAPEUTICS INC | $7.0M | 6.79% |
| 5 | LKFT GALAPAGOS NV | $6.2M | 6.05% |
| 6 | ALLK ALLAKOS INC | $5.2M | 5.1% |
| 7 | SGEN SEAGEN INC | $4.8M | 4.71% |
| 8 | AVIR ATEA PHARMACEUTICALS INC | $4.6M | 4.5% |
| 9 | SAGE SAGE THERAPEUTICS INC | $4.5M | 4.42% |
| 10 | AMRN AMARIN CORP PLC | $4.5M | 4.39% |
| 11 | IRWD IRONWOOD PHARMACEUTICALS INC | $4.0M | 3.93% |
| 12 | SANA SANA BIOTECHNOLOGY INC | $4.0M | 3.9% |
| 13 | ALKS ALKERMES PLC | $3.7M | 3.61% |
| 14 | SYRS SYROS PHARMACEUTICALS INC | $3.1M | 3.03% |
| 15 | KPTI KARYOPHARM THERAPEUTICS INC | $3.0M | 2.97% |
| 16 | NKTR NEKTAR THERAPEUTICS | $3.0M | 2.93% |
| 17 | RNAC SELECTA BIOSCIENCES INC | $2.9M | 2.81% |
| 18 | BHVN BIOHAVEN LTD | $2.5M | 2.42% |
| 19 | RCKT ROCKET PHARMACEUTICALS INC | $2.4M | 2.38% |
| 20 | MRTX MIRATI THERAPEUTICS INC | $2.2M | 2.09% |
Values as reported on the Q4 2022 Form 13F. Every position is in the holdings table below.